Plitidepsin

Summary

Plitidepsin (CHEMBL451930) is an approved small-molecule antineoplastic agent (ATC L01XX57); indicated across 7 conditions including neoplasm and plasma cell myeloma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XX57
• Indications: 7 conditions
• Clinical trials: 11
• Chemistry: 1110.3 Da · C57H87N7O15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL451930
Name	Plitidepsin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9812534
ChEBI	CHEBI:90205
ATC	L01XX57
Molecular formula	C57H87N7O15
Molecular weight	1110.3
InChIKey	UUSZLLQJYRSZIS-LXNNNBEUSA-N

SMILES: CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O

IUPAC name: (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide

ChEBI definition: A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.

Pharmacological roles (ChEBI): antineoplastic agent, anticoronaviral agent.

Other ChEBI roles (chemical / environmental): marine metabolite.

Also known as: Aplidine, Plitidepsin, Plitidepsina, Plitidepsine, dehydrodidemnin B, PLITIDEPSIN, Dehydrodidemnin B; Plitidepsin

Patent coverage: 1,356 distinct patent families (3,093 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
dedifferentiated liposarcoma	2	MONDO:0020563	EFO:0003085
lymphoma	2	MONDO:0005062	EFO:0000574
primary myelofibrosis	2	MONDO:0009692	MONDO:0044903

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01102426	PHASE3	COMPLETED	Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT04784559	PHASE3	TERMINATED	Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT06766825	PHASE2	RECRUITING	Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
NCT00229203	PHASE2	COMPLETED	A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
NCT01876043	PHASE2	TERMINATED	Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
NCT03070964	PHASE2	TERMINATED	A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
NCT03117361	PHASE2	TERMINATED	Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
NCT05705167	PHASE2	TERMINATED	Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
NCT00788099	PHASE1	COMPLETED	Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
NCT02100657	PHASE1	COMPLETED	Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
NCT04382066	PHASE1	COMPLETED	Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).